Marshall Wace, LLP Humanigen, Inc Transaction History

Marshall Wace, LLP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.76 - $3.33 $1.1 Million - $2.08 Million	-624,232 Reduced 50.63%	608,736 $1.08 Million
Q1 2022 May 16, 2022	BUY	$1.81 - $3.97 $288,814 - $633,477	159,566 Added 14.87%	1,232,968 $3.71 Million
Q4 2021 Feb 14, 2022	BUY	$3.66 - $8.22 $2.44 Million - $5.47 Million	665,839 Added 163.37%	1,073,402 $3.99 Million
Q2 2021 Aug 13, 2021	SELL	$13.54 - $22.74 $984,425 - $1.65 Million	-72,705 Reduced 15.14%	407,563 $7.08 Million
Q1 2021 May 17, 2021	BUY	$12.91 - $23.83 $6.2 Million - $11.4 Million	480,268 New	480,268 $9.17 Million

558K

Ticker HGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,661,000
Description
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.